CN104672210A - 阿格列汀和苯甲酸阿格列汀的制备方法 - Google Patents
阿格列汀和苯甲酸阿格列汀的制备方法 Download PDFInfo
- Publication number
- CN104672210A CN104672210A CN201310628452.XA CN201310628452A CN104672210A CN 104672210 A CN104672210 A CN 104672210A CN 201310628452 A CN201310628452 A CN 201310628452A CN 104672210 A CN104672210 A CN 104672210A
- Authority
- CN
- China
- Prior art keywords
- egelieting
- preparation
- solid
- methyl
- virahol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 229960001667 alogliptin Drugs 0.000 title abstract description 10
- KEJICOXJTRHYAK-XFULWGLBSA-N alogliptin benzoate Chemical compound OC(=O)C1=CC=CC=C1.C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 KEJICOXJTRHYAK-XFULWGLBSA-N 0.000 title abstract description 5
- 229960000447 alogliptin benzoate Drugs 0.000 title abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 35
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000007787 solid Substances 0.000 claims abstract description 22
- 238000001914 filtration Methods 0.000 claims abstract description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 12
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- GGPNYXIOFZLNKW-ZJIMSODOSA-N (3r)-piperidin-3-amine;dihydrochloride Chemical compound Cl.Cl.N[C@@H]1CCCNC1 GGPNYXIOFZLNKW-ZJIMSODOSA-N 0.000 claims abstract description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 11
- 235000015320 potassium carbonate Nutrition 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 5
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims description 3
- 239000012065 filter cake Substances 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000003610 charcoal Substances 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 19
- 239000007810 chemical reaction solvent Substances 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract description 2
- 239000005711 Benzoic acid Substances 0.000 abstract 1
- PJVOHTUINMMGSE-UHFFFAOYSA-L C(C)(C)O.C([O-])([O-])=O.[K+].[K+] Chemical compound C(C)(C)O.C([O-])([O-])=O.[K+].[K+] PJVOHTUINMMGSE-UHFFFAOYSA-L 0.000 abstract 1
- 235000010233 benzoic acid Nutrition 0.000 abstract 1
- IHDSPDZERWPDQJ-UHFFFAOYSA-L disodium propan-2-ol carbonate Chemical compound C([O-])([O-])=O.[Na+].C(C)(C)O.[Na+] IHDSPDZERWPDQJ-UHFFFAOYSA-L 0.000 abstract 1
- 229910000027 potassium carbonate Inorganic materials 0.000 abstract 1
- 239000000047 product Substances 0.000 description 17
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 229910052708 sodium Inorganic materials 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 9
- 102100040918 Pro-glucagon Human genes 0.000 description 9
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 8
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methyl alcohol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- BVUJISIVAHYNLI-UHFFFAOYSA-N 2-[(6-chloro-3-methyl-2,4-dioxopyrimidin-1-yl)methyl]benzonitrile Chemical compound O=C1N(C)C(=O)C=C(Cl)N1CC1=CC=CC=C1C#N BVUJISIVAHYNLI-UHFFFAOYSA-N 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- XWIVQTCOKAUMSR-UHFFFAOYSA-N C(CCC)N(CCCC)CCCC.C(CCC)O Chemical compound C(CCC)N(CCCC)CCCC.C(CCC)O XWIVQTCOKAUMSR-UHFFFAOYSA-N 0.000 description 2
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 2
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
- PEUGKEHLRUVPAN-RXMQYKEDSA-N (3r)-piperidin-3-amine Chemical compound N[C@@H]1CCCNC1 PEUGKEHLRUVPAN-RXMQYKEDSA-N 0.000 description 1
- OBRAPVFBWRZVKS-UHFFFAOYSA-L C([O-])([O-])=O.[Cs+].C(CCC)O.[Cs+] Chemical compound C([O-])([O-])=O.[Cs+].C(CCC)O.[Cs+] OBRAPVFBWRZVKS-UHFFFAOYSA-L 0.000 description 1
- 0 C*c1ccccc1 Chemical compound C*c1ccccc1 0.000 description 1
- ZRVZFFYDPVVCJX-UHFFFAOYSA-N CC(CCC1)CN1C(N(Cc1ccccc1C=C)C(N1C)=N)=CC1=C Chemical compound CC(CCC1)CN1C(N(Cc1ccccc1C=C)C(N1C)=N)=CC1=C ZRVZFFYDPVVCJX-UHFFFAOYSA-N 0.000 description 1
- KIURVJQOZGWWCT-UHFFFAOYSA-N CCCN(CCC#N)C(N(Cc1ccccc1C#N)C(N1C)=O)=CC1=C Chemical compound CCCN(CCC#N)C(N(Cc1ccccc1C#N)C(N1C)=O)=CC1=C KIURVJQOZGWWCT-UHFFFAOYSA-N 0.000 description 1
- LZAVMPFPKYPBAX-JTQLQIEISA-N CN(C(C=C(N1C[C@H]2C(C#N)=CC=CC2)Cl)=O)C1=O Chemical compound CN(C(C=C(N1C[C@H]2C(C#N)=CC=CC2)Cl)=O)C1=O LZAVMPFPKYPBAX-JTQLQIEISA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- PEUGKEHLRUVPAN-UHFFFAOYSA-N NC1CNCCC1 Chemical compound NC1CNCCC1 PEUGKEHLRUVPAN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical group OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310628452.XA CN104672210B (zh) | 2013-11-29 | 2013-11-29 | 阿格列汀和苯甲酸阿格列汀的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310628452.XA CN104672210B (zh) | 2013-11-29 | 2013-11-29 | 阿格列汀和苯甲酸阿格列汀的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104672210A true CN104672210A (zh) | 2015-06-03 |
CN104672210B CN104672210B (zh) | 2018-05-11 |
Family
ID=53307851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310628452.XA Expired - Fee Related CN104672210B (zh) | 2013-11-29 | 2013-11-29 | 阿格列汀和苯甲酸阿格列汀的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104672210B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107540656A (zh) * | 2016-06-29 | 2018-01-05 | 常州市第四制药厂有限公司 | 一种苯甲酸阿格列汀的制备方法 |
CN109232532A (zh) * | 2018-11-08 | 2019-01-18 | 重庆科瑞南海制药有限责任公司 | 一种苯甲酸阿格列汀的工业化生产方法 |
CN109810094A (zh) * | 2019-01-31 | 2019-05-28 | 深圳市第二人民医院 | 一种阿格列汀的制备方法 |
CN113698384A (zh) * | 2021-10-26 | 2021-11-26 | 上海维京生物医药科技有限公司 | 阿格列汀没食子酸盐及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101360723A (zh) * | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
CN101360735A (zh) * | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 2-[[6-[(3r)-3-氨基-1-哌啶基]-3,4-二氢-3-甲基-2,4-二氧代-1(2h)-嘧啶基]甲基]-苄腈的苯甲酸盐的多晶型物及其使用方法 |
CN102942556A (zh) * | 2012-12-04 | 2013-02-27 | 成都天翼医药科技有限公司 | 一种苯甲酸阿格列汀的制备工艺 |
-
2013
- 2013-11-29 CN CN201310628452.XA patent/CN104672210B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101360723A (zh) * | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
CN101360735A (zh) * | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 2-[[6-[(3r)-3-氨基-1-哌啶基]-3,4-二氢-3-甲基-2,4-二氧代-1(2h)-嘧啶基]甲基]-苄腈的苯甲酸盐的多晶型物及其使用方法 |
CN102942556A (zh) * | 2012-12-04 | 2013-02-27 | 成都天翼医药科技有限公司 | 一种苯甲酸阿格列汀的制备工艺 |
Non-Patent Citations (1)
Title |
---|
刘昭文等: "苯甲酸阿格列汀的合成", 《海峡药学》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107540656A (zh) * | 2016-06-29 | 2018-01-05 | 常州市第四制药厂有限公司 | 一种苯甲酸阿格列汀的制备方法 |
CN109232532A (zh) * | 2018-11-08 | 2019-01-18 | 重庆科瑞南海制药有限责任公司 | 一种苯甲酸阿格列汀的工业化生产方法 |
CN109810094A (zh) * | 2019-01-31 | 2019-05-28 | 深圳市第二人民医院 | 一种阿格列汀的制备方法 |
CN109810094B (zh) * | 2019-01-31 | 2021-11-12 | 深圳市第二人民医院 | 一种阿格列汀的制备方法 |
CN113698384A (zh) * | 2021-10-26 | 2021-11-26 | 上海维京生物医药科技有限公司 | 阿格列汀没食子酸盐及其制备方法和应用 |
CN113698384B (zh) * | 2021-10-26 | 2022-01-18 | 上海维京生物医药科技有限公司 | 阿格列汀没食子酸盐及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104672210B (zh) | 2018-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2565205B1 (en) | Glucagon-like peptide-1 analogue and use thereof | |
CN105968093B (zh) | 琥珀酸曲格列汀的制备方法 | |
CN102757415A (zh) | 一种钠依赖性葡萄糖转运蛋白抑制剂及其制备方法和用途 | |
CN104672210A (zh) | 阿格列汀和苯甲酸阿格列汀的制备方法 | |
CN102942556A (zh) | 一种苯甲酸阿格列汀的制备工艺 | |
CN102186881B (zh) | 胰高血糖素样肽-1衍生物及其应用 | |
CN107188893B (zh) | 一种西格列汀杂质的制备方法 | |
CN104592195A (zh) | 一种苯甲酸阿格列汀的制备方法 | |
CN103030631B (zh) | 用于制备嘧啶二酮类dpp-iv抑制剂的化合物 | |
CN103275209A (zh) | 制备利拉鲁肽的方法 | |
CN104059042A (zh) | C-三芳基葡萄糖苷类sglt-2抑制剂 | |
CN105646446A (zh) | 一种纯化阿格列汀的方法 | |
CN109810094B (zh) | 一种阿格列汀的制备方法 | |
CN114516837B (zh) | 荷叶碱衍生物及其制备方法和应用 | |
CN106749228B (zh) | 一种小檗碱药物及其制备方法与应用 | |
CN105085475B (zh) | 一种合成阿格列汀中间体的方法 | |
CN101550112B (zh) | 4,5-二取代噻唑衍生物、其制备方法和用途 | |
CN102229668A (zh) | 一种glp-1衍生物及其应用 | |
CN107540656A (zh) | 一种苯甲酸阿格列汀的制备方法 | |
CN103159640A (zh) | 那格列奈原料的制备方法 | |
CN105001197A (zh) | 一种阿格列汀衍生物ⅰ及其制备方法与应用 | |
CN110684026A (zh) | 一种利格列汀的工业化制备方法 | |
CN109096133A (zh) | (s)-2-氨基-3-(2,4,5-三氟苯基)丙酸薄荷酯盐酸盐及其制备方法和应用 | |
CN110092799B (zh) | 一种环状化合物、其制备方法和应用 | |
CN103732584A (zh) | 哌嗪类衍生物及其制备方法以及在治疗胰岛素抵抗中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221017 Address after: 3007, Hengqin international financial center building, No. 58, Huajin street, Hengqin new area, Zhuhai, Guangdong 519031 Patentee after: New founder holdings development Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: Peking University Medical Management Co.,Ltd. Address before: 100871, fangzheng building, 298 Fu Cheng Road, Beijing, Haidian District Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: PKU HEALTHCARE INDUSTRY Group |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180511 |
|
CF01 | Termination of patent right due to non-payment of annual fee |